From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Medicago to Develop Sudan Strain Ebola Antibodies

by Global Biodefense Staff
November 5, 2015
Ebola Monoclonal Antibody Countermeasures

Public Health Agency of Canada (PHAC) has awarded new funding to Medicago, a plant-based biopharmaceutical company, to develop two antibodies to fight the Sudan strain of the Ebola virus.

The effort builds on existing research by these organizations directed at the Ebola Zaire strain, responsible for the ongoing outbreak in West Africa.

According to the World Health Organization (WHO), the Ebola Sudan strain has previously been associated with large-scale outbreaks in Africa. The availability of an effective antibody would allow for an early intervention in case of a new outbreak involving the Sudan strain.

“Medicago will be using its technology and manufacturing system to collaborate with the Canadian government to provide a solution for the possible re-emergence of this devastating disease,” said Andy Sheldon, CEO of Medicago. “We are also proud to work on a Canadian solution that can be employed as a response to other biological threats that may impact national and international security in the future.

Medicago’s innovative technology uses plants as miniature factories that can quickly produce large quantities of vaccines or antibodies. This technology demonstrated its potential for responding to global pandemics when it produced candidate vaccines for H1N1 in 2009 and H7N9 in 2013 in just 19 days, compared to the several months required to produce vaccines using eggs.

Prior to this award, Medicago successfully completed the recent contract signed with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to explore an alternate production method for Ebola antibodies against the Zaire strain.

From Our Partners
Tags: ASPRAwardsBARDAEbolaEmerging ThreatsHHS

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC